Nottingham, United Kingdom, October 2, 2026
Quotient Sciences and Acesion Pharma have announced a collaboration focused on using artificial intelligence (AI) to enhance formulation development and accelerate the progression of pharmaceutical candidates toward clinical development. The collaboration brings together Quotient Sciences’ expertise in drug development and formulation with Acesion Pharma’s AI-enabled drug discovery and development capabilities. The companies aim to apply advanced computational approaches to formulation challenges, potentially improving the speed and efficiency with which drug candidates are developed into suitable pharmaceutical products. The collaboration reflects the pharmaceutical industry’s increasing adoption of AI and data-driven technologies across the drug development lifecycle, particularly in areas where formulation optimization can influence clinical performance, manufacturability, and development timelines.
AI-Enhanced Formulation Development
Formulation development is a critical stage in pharmaceutical research because a promising drug candidate must ultimately be converted into a stable and deliverable medicine. Researchers need to evaluate factors such as solubility, stability, dissolution, bioavailability, excipient compatibility, and drug-release characteristics when selecting an appropriate formulation. These processes can require extensive laboratory experimentation and iterative optimization. The collaboration between Quotient Sciences and Acesion Pharma is designed to introduce AI-enhanced approaches into this process. By combining computational analysis with experimental formulation development, the companies aim to identify promising formulation strategies more efficiently and potentially reduce the number of experimental cycles required. AI can analyze large datasets and identify relationships between formulation components and drug performance that may not be immediately apparent through conventional approaches. When combined with laboratory-generated evidence, these insights can support more informed decisions during pharmaceutical development. For drug developers, the potential benefits include faster formulation optimization, improved decision-making, and more efficient use of development resources. These capabilities could become increasingly important as pharmaceutical pipelines include more complex molecules and drug candidates with challenging physical and chemical properties.
Collaboration Supports Faster Drug Development
The partnership builds on the complementary capabilities of the two organizations. Quotient Sciences provides integrated drug development services covering areas such as formulation, clinical development, and pharmaceutical sciences. Its experience in translating drug candidates from early development toward clinical studies provides an important foundation for applying AI-based formulation strategies in practical development programs. Acesion Pharma brings expertise in innovative drug discovery and development, with a focus on identifying and advancing novel therapeutic candidates. The collaboration is intended to connect computational technologies with real-world formulation development, helping transform scientific insights into viable pharmaceutical products. The integration of AI with pharmaceutical development expertise could help companies address formulation challenges earlier in the drug development process. Identifying potential problems with stability or drug delivery at an early stage may reduce delays and enable development teams to make better-informed decisions before programs reach more advanced stages.
Advertisement
AI Gains Momentum Across Pharmaceutical R&D
The Quotient Sciences-Acesion Pharma collaboration highlights a broader trend toward the use of artificial intelligence in pharmaceutical research and development. AI is increasingly being explored for applications ranging from target identification and molecule design to clinical trial planning, data analysis, manufacturing, and formulation optimization. Formulation is particularly suitable for data-driven approaches because researchers can evaluate relationships between numerous variables, including drug properties, excipient combinations, manufacturing conditions, and performance characteristics. AI-supported models may help identify patterns and prioritize experiments, while laboratory testing remains essential for validating predictions.
The collaboration therefore represents an important development at the intersection of AI, formulation science, and drug development. By combining computational tools with established pharmaceutical development capabilities, the companies aim to improve the efficiency of formulation programs and support the advancement of promising therapeutic candidates. As pharmaceutical companies continue seeking ways to shorten development timelines while maintaining product quality, AI-enhanced formulation development could become an increasingly important component of modern drug development strategies. The partnership between Quotient Sciences and Acesion Pharma demonstrates how collaboration between technology-driven and pharmaceutical-development organizations can contribute to the evolution of more efficient R&D workflows.
Source: Quotient Sciences, Acesion Pharma press release
